TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24224808
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with rabeprazole 10 mg b.i.d./q.i.d., amoxicillin 500 mg q.i.d, and sitafloxacin 100 mg b.i.d. (RAS) for 1 week
Study: 24224808
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with rabeprazole 10 mg b.i.d./q.i.d., amoxicillin 500 mg q.i.d, and sitafloxacin 100 mg b.i.d. (RAS) for 2 weeks
Study: 24224808
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with rabeprazole 10 mg b.i.d./q.i.d., metronidazole 250 mg b.i.d., and sitafloxacin 100 mg b.i.d. (RMS) for 2 weeks
Study: 22209180
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of 8 mg dexamethasone
Study: 15297045
Drug: antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiretroviral therapy alone
Study: 9299805
Drug: BIGCBT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIGCBT plus anti-anxiety medication
Study: 26739717
Drug: KB003 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: KB003 (400 mg)
Study: 24472704
Drug: Quercetin (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (single-dose and repeated intake)
Study: 20718771
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU; 1000 mg IM)
Study: 17620637
Drug: Glucantime 60
Normalized name: Glucantim
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucantime 60 mg/kg intramuscular for 20 days
Study: 24550171
Drug: Sarilumab 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 100 mg every other week
Study: 24550171
Drug: Higher sarilumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher sarilumab doses
Study: 24550171
Drug: Sarilumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab treatment groups
Study: 20949263
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (Amonate FDC tablets; AS 50 mg and AQ 200 mg)
Study: 19395364
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 400 microg every 3 h for five doses
Study: 16374601
Drug: Lorazepam administration
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam administration
Study: 11252467
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g Cr + 20 g glucose per day, n=9)
Study: 11252467
Drug: Placebo (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (40 g glucose per day, n=9)
Study: 8323210
Drug: Chloroform water
Normalized name: chloroform water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroform water 5 ml/day with 1 mg of iodine for 20 weeks
Study: 8323210
Drug: Chloroform water
Normalized name: chloroform water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroform water 5 ml/day (placebo)
Study: 3162993
Drug: Routine stomatognathic
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine stomatognathic treatment including an occlusal splint (S group)
Study: 28760384
Drug: Relamorelin 10
Normalized name: Relamorelin
DrugBank: Relamorelin (DB12678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relamorelin 10 μg
Study: 28760384
Drug: Relamorelin 30
Normalized name: Relamorelin
DrugBank: Relamorelin (DB12678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relamorelin 30 μg
Study: 28760384
Drug: Relamorelin 100
Normalized name: Relamorelin
DrugBank: Relamorelin (DB12678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relamorelin 100 μg
Study: 9476038
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (75 mg once daily for 7 days)
Study: 3661953
Drug: Self-taming with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-taming with suxamethonium (4 mg i.v. after induction, remaining dose applied one minute later)
Study: 26864207
Drug: mite allergoid
Normalized name: mite extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: mite allergoid SCIT 50 000 AUeq/ml
Study: 26864207
Drug: mite allergoid
Normalized name: mite extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: mite allergoid SCIT 6667 AUeq/ml
Study: 26864207
Drug: mite allergoid
Normalized name: mite extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: mite allergoid SCIT 100 000 AUeq/ml
Study: 25072595
Drug: ACT1 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT1 gel formulation plus standard-of-care (SOC) protocols
Study: 25072595
Drug: ACT1 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT1 therapy
Study: 21840002
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (240 mg/day of zinc as zinc gluconate)
Study: 19019730
Drug: Crataegus extract
Normalized name: crataegus extract
DrugBank: Hawthorn leaf with flower (DB15839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crataegus extract WS 1442 (900 mg/day)
Study: 11106919
Drug: Pirenzepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (100 mg) plus GHRH (100 microg, i.v.)
Study: 6375711
Drug: Mantle radiotherapy
Normalized name: garden lady's mantle extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mantle radiotherapy followed by 6 courses of adjuvant chemotherapy with mustine, vinblastine, prednisolone and procarbazine (MVPP)
Study: 29470731
Drug: Personalized conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized conservative treatment (PCT)
Study: 20811918
Drug: 8% lidocaine
Normalized name: LIDOCAINE 18 g in 100 g TOPICAL CREAM [Tattoo Numbing Cream 18% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% lidocaine spray 10 min prior to intubation and ETTs lubricated with normal saline (Group E)
Study: 20811918
Drug: 8% lidocaine
Normalized name: LIDOCAINE 18 g in 100 g TOPICAL CREAM [Tattoo Numbing Cream 18% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% lidocaine spray immediately before intubation and ETTs lubricated with normal saline (Group B)
Study: 20811918
Drug: 8% lidocaine
Normalized name: LIDOCAINE 18 g in 100 g TOPICAL CREAM [Tattoo Numbing Cream 18% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% lidocaine spray immediately before intubation and ETTs lubricated with 2% lidocaine gel (Group A)
Study: 11758183
Drug: CEE 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.3 mg/d + MPA 2 mg/d + Ca‐D 600 mg/d
Study: 11758183
Drug: Ca‐D 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca‐D 600 mg/d only (control)
Study: 11758183
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg/d + MPA 2 mg/d + Ca‐D 600 mg/d
Study: 25500307
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10mg daily for 18 weeks)
Study: 19384265
Drug: Vitamin supplementation
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin supplementation (2 mg of folic acid, 25 mg vitamin B6, and 400 microg of vitamin B12)
Study: 7605876
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg Aprosulate b.i.d. s.c.
Study: 7605876
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg Aprosulate o.d. + placebo o.d. s.c.
Study: 2083173
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg garlic powder per day (equivalent to 2,700 mg of fresh garlic)
Study: 392620
Drug: PGE2 3
Normalized name: PGE2 3 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 3 mg vaginal vault
Study: 392620
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg PGE2 vaginal pessary
Study: 28912593
Drug: PTT mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTT mixture (200 mg) postprandial
Study: 28912593
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules postprandial
Study: 17241422
Drug: BTX‐A at
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTX‐A at 100 U/mL
Study: 17241422
Drug: BTX‐A at
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTX‐A at 33.3 U/mL
Study: 17241422
Drug: BTX‐A at
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTX‐A at 20 U/mL
Study: 17241422
Drug: BTX‐A at
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTX‐A at 10 U/mL
Study: 15491984
Drug: Modified control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified control group (MCG)
Study: 25582850
Drug: NaFeEDTA-fortified soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaFeEDTA-fortified soy sauce (6 mg Fe)
Study: 25582850
Drug: FeSO₄-fortified soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: FeSO₄-fortified soy sauce (6 mg Fe)
Study: 20677441
Drug: Drug effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug effect
Study: 15985101
Drug: Delayed ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed ketorolac monotherapy (two 15-mg boluses) 4 hours after onset of attack.
Study: 15985101
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of COX1/COX2 inhibitors (ketorolac 0.4 mg/kg or indomethacin 1 mg/kg) in rats.
Study: 12455318
Drug: Metamizol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizol (2 g intravenous)
Study: 12455318
Drug: Propacetamol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol (2 g intravenous)
Study: 2289218
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg of citicoline daily plus usual dose of levodopa (mean, 381 mg daily)
Study: 31385920
Drug: Recommendations for
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommendations for treatment
Study: 28789490
Drug: Testa triticum
Normalized name: Triticum aestivum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testa triticum tricum purif (3.5 g bid)
Study: 15163110
Drug: Ultrasonographically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonographically guided peritendinous injection of steroid
Study: 9790158
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg/day
Study: 20102894
Drug: CRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP levels > or =2 mg/L
Study: 20102894
Drug: CRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP levels <2 mg/L
Study: 7674143
Drug: Low-dose SH/TA-508
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose SH/TA-508 (1.5-1.6g galactose)
Study: 1353506
Drug: Pindolol (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (0.04 mg/kg)
Study: 24486563
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (16 IU)
Study: 2558700
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion (0.4 nmol kg‐1 min‐1)
Study: 30985671
Drug: Sham laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham laser acupuncture treatment
Study: 30985671
Drug: Real laser
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real laser acupuncture treatment (LAT)
Study: 21595618
Drug: Pure tone
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure tone masking‐tinnitus retraining therapy (TRT)
Study: 12622930
Drug: lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamivudine 100 mg daily (n = 322)
Study: 7486295
Drug: Vecuronium (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.08 mg.kg-1)
Study: 1936510
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg diflunisal given orally twice daily plus placebo twice daily for 3 days
Study: 7117684
Drug: Two 165
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 165 mg ultramicrosize griseofulvin tablets
Study: 28559749
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy program plus SNAG (3 times per week for 1 month)
Study: 28559749
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy program without SNAG (3 times per week for 1 month)
Study: 26270684
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for asymptomatic bacteriuria (AB) in group B
Study: 26270684
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for asymptomatic bacteriuria in group A
Study: 25022130
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication alone
Study: 22526517
Drug: FLU 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLU 1200 mg/day + 5-FC 100 mg/kg/day for 14 days + AmB 1 mg/kg/day for 7 days
Study: 22526517
Drug: FLU 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLU 1200 mg/day + AmB 1 mg/kg/day for 7 days
Study: 22526517
Drug: FLU 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLU 1200 mg/day + 5-FC 100 mg/kg/day for 14 days
Study: 17329297
Drug: Ispronicline 50
Normalized name: Ispronicline
DrugBank: Ispronicline (DB16205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ispronicline 50 mg
Study: 17329297
Drug: Ispronicline 100
Normalized name: Ispronicline
DrugBank: Ispronicline (DB16205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ispronicline 100 mg
Study: 17329297
Drug: Ispronicline 150
Normalized name: Ispronicline
DrugBank: Ispronicline (DB16205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ispronicline 150 mg
Study: 17447826
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (specifically olanzapine)
Study: 7543344
Drug: Inhaled acetaldehyde
Normalized name: acetaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled acetaldehyde
Study: 1628727
Drug: Inhaled histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled histamine
Study: 238792
Drug: 30 mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg. dihydrochloride salt of flurazepam
Study: 8505112
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal diet plus placebo capsule)
Study: 28316019
Drug: Rebamipide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide (100 mg single oral dose)
Study: 2518952
Drug: Whole virus
Normalized name: rabies, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole virus vaccine
Study: 30385541
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy plus TENMS
Study: 30385541
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy alone (control group)
Study: 2686478
Drug: Haloperidol 5
Normalized name: haloperidol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 5 mg and Phenobarbital sodium 130 mg
Study: 5114822
Drug: Marihuana smoke
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marihuana smoke administration
Study: 29197080
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml boluses of bupivacaine 0.0625% + fentanyl 2 μg.ml‐1 at a 40 min interval
Study: 21911741
Drug: Placebo (identical-looking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical-looking capsules)
Study: 18368834
Drug: Ondansetron as
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron as lingual tablets
Study: 18368834
Drug: Ondansetron as
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron as syrup
Study: 11820367
Drug: Tonsillar immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonsillar immunization with glucosyltransferase-enriched preparation (E-GTF)
Study: 8674466
Drug: Haloperidol (HAL)
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol (HAL) administered orally at three fixed doses: 6 mg per day, 10 mg per day, and 15 mg per day for 2 weeks.
Study: 2105256
Drug: Isocaloric, isonitrogenous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric, isonitrogenous, low‐sodium standard oral diet (n = 19)
Study: 7408673
Drug: Irrigation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigation treatment with Capmul 8210
Study: 25616294
Drug: High-dose amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose amino acids (3.0 g/kg per day, increasing by 0.5-1.0 g/kg daily, max 4.0 g/kg per day)
Study: 25616294
Drug: Medium-dose amino
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose amino acids (2.0 g/kg per day, increasing by 1.0 g/kg daily, max 3.7 g/kg per day)
Study: 25616294
Drug: Low-dose amino
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amino acids (1.0 g/kg per day, increasing by 1.0 g/kg daily, max 3.5 g/kg per day)
Study: 25616294
Drug: High-dose amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose amino acids (3.0 g/kg per day)
Study: 25616294
Drug: Low-dose amino
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amino acids (1.0 g/kg per day)
Study: 20374582
Drug: Day surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day surgery microwave endometrial ablation after standard drug-based endometrial preparation
Study: 8218757
Drug: Telenzepine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telenzepine (3 mg p.o.)
Study: 3326525
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg
Study: 18640464
Drug: DIO-902 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIO-902 200 mg
Study: 18640464
Drug: DIO-902 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIO-902 400 mg
Study: 18640464
Drug: DIO-902 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIO-902 600 mg
Study: 18640464
Drug: DIO-902 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIO-902 (all doses)
Study: 16155269
Drug: Cobalamin capsule
DrugBank: Cobalamin (DB14098)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cobalamin capsule with 1000 microg crystalline cobalamin
Study: 9825270
Drug: SPA-S-565 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPA-S-565 (150 mg)
Study: 9825270
Drug: Rifampicin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (150 mg)
Study: 24075779
Drug: Single-agent trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent trastuzumab or lapatinib
Study: 17496418
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no drug)
Study: 15374707
Drug: 17beta‐estradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐estradiol (2 mg) + norethisterone acetate (1 mg; E(2)‐NETA)
Study: 9825188
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg moexipril hydrochloride (single oral dose)
Study: 2576423
Drug: Gradual Withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual Withdrawal (GW) group (n=16) received temazepam 5 mg for the first 4 nights, 2 mg for the next 4 nights, and placebo for the last 2 nights
Study: 29516486
Drug: Hydromorphone 1
Normalized name: HYDROMORPHONE 1MG/ML NS INJ 50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 1 mg IV
Study: 26374430
Drug: Multicomponent exercise
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent exercise training programme (supervised progressive resistance exercise training, balance-training, and walking for 5-7 consecutive days, 20 min sessions twice a day)
Study: 24074360
Drug: DHA 500
Normalized name: ASHWAGANDHA 500mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA 500 mg/day
Study: 21233083
Drug: DHA 250
Normalized name: DHA 250 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA 250 mg/day and DHA 500 mg/day
Study: 17535990
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention (baseline measurements before trial supplements)
Study: 15161067
Drug: Intranasal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal vaccination with CRM197 alone
Study: 15161067
Drug: Intranasal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal vaccination with CRM197 formulated with chitosan
Study: 15161067
Drug: Parenteral immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral immunization with conventional diphtheria toxoid vaccine
Study: 11963647
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ambroxol hydrochloride lozenges
Study: 7867830
Drug: Topical acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acyclovir ointment, 5 times daily for 7 days
Study: 7867830
Drug: Oral acyclovir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acyclovir, 800 mg, 5 times daily for 7 days
Study: 1272683
Drug: Reinforcement administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforcement administered on a fixed ratio (FR4) schedule
Study: 29985719
Drug: BEMER therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEMER therapy combined with rehabilitation for 10 consecutive days